Tisotumab vedotin CD markers inhibitor | Read Reviews & Product Use Citations

Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer.

CAS No. 1418731-10-8

Click to purchase products related to Tisotumab vedotin

Quality Control

Batch: Purity: 99% Protein concentration: 9.162mg/ml Endotoxin Level: ＜1EU/mg

99

Specificity

Name	Citation	CD38	CD45	CD39	CD88	CD73	Others
RBN013209	0	++
MK-0159	0	+++
CD38 inhibitor 1 (compound 78c)	7	+++
AB680	0					++++
NQ301	1		+				TXA2 receptor
SodiuM Metatungstate	3			++
PMX-53	3				✔
LY-3475070	2					✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer.
References	[1] https://pubmed.ncbi.nlm.nih.gov/35962528/ [2] https://pubmed.ncbi.nlm.nih.gov/35932175/

Description

Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer.

References

[1] https://pubmed.ncbi.nlm.nih.gov/35962528/
[2] https://pubmed.ncbi.nlm.nih.gov/35932175/

Product Details

CAS No.	1418731-10-8
DAR	4.2
ADC antiody	Tisotumab
ADC cytotoxin	MMAE
Formulation	1xPBS
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.